Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics

  • Heerlein, K.
  • Young, Allan H.
  • Otte, C.
  • Frodl, T.
  • Degraeve, G.
  • Hagedoorn, W.
  • Oliveira Maia, A. J.
  • Pérez Solà, Víctor
  • Rathod, S.
  • Rosso, G.
  • Sierra, Pablo
  • Morrens, J.
  • Van Dooren, G.
  • Gali, Y.
  • Perugi, G.
Background: Treatment resistant depression (TRD; failure to respond to ≥2 treatments) affects ~20% of patients with major depressive disorder (MDD). Real-world data could help describe patient characteristics and TRD disease burden, to assess the unmet needs of TRD patients in Europe. Methods: This observational study collected data from adults with moderate to severe TRD initiating a new treatment for depression, according to local standards of care. At baseline, socio-demographic characteristics, medical history, prior and current treatments were recorded. Disease severity, health-related quality of life (HRQoL), functionality and productivity were assessed. Results: Overall, 411 eligible patients were enrolled across seven European countries. Mean (standard deviation [SD]) patient age was 51.0 (10.8) years; 62.3% were female. Long-term sick leave was reported by 19.0% of patients; 30.2% were unemployed. The mean (SD) duration of the current episode was 2.6 (3.9) years. At baseline, mean (SD) HRQoL scores for EuroQoL 5-dimension 5-level (UK tariff) and EQ-Visual Analog Scale were 0.41 (0.25) and 41.1 (18.7), respectively. The Work Productivity and Activity Impairment questionnaire demonstrated mean (SD) absenteeism of 57.0% (44.9%) and presenteeism of 54.7% (29.5%); mean (SD) overall work impairment was 60.5% (29.9%). Limitations: Key limitations are small cohort size, absence of a control group and generalizability to countries with different healthcare models. Conclusions: TRD patients had a high disease burden, low HRQoL and reduced function and productivity, with a substantial proportion unable to work. This demonstrates an unmet treatment need in TRD patients that, if addressed, could reduce the heavy personal and societal burden., KH: Employee of Janssen EMEA; AHY: Grants from Janssen; speaker/consultant for Allegan, AstraZeneca, Bionomics, Eli Lilly, Janssen, Johnson & Johnson, Livanova, Lundbeck, Servier, Sumitomo Dainippon Pharma and Sunovion; independent research is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health; CO: Speaker/consultant for Allergan, Ferring, Fortbildungskolleg, Limes Kliniken, MedOnline, Medical Tribune, Neuraxpharm, Sage Therapeutics, and Stillachhaus; Research funding from Deutsche Forschungsgemeinschaft, German Federal Ministry of Education and Research and European Union; TF: Speaker for Janssen-Cilag and Recordati; GD: Consultant/speaker for AstraZeneca, BMS, Eli Lilly, EuroGenerics, GSK, Janssen, Lundbeck, Pfizer and Sanofi; WH: Consultant for Janssen; AJOM: Grants from Schuhfried GmBH, Janssen and Compass Pathways, Ltd; investigator-driven research funded by Fundação para Ciência e Tecnologia (PTDC/MED-NEU/31331/2017), Fundação para Ciência e Tecnologia and FEDER (FCT-PTDC/MEC-PSQ/30302/2017-IC&DTLISBOA-01-0145-FEDER) and the European Commission Horizon 2020 program (H2020-SC1-2017-CNECT-2-777167-ΒΟUNCE; H2020-SC1-DTH-2019-875358-FAITH); VPS: Consultancy fees, honoraria or grants from AB-Biotics, AstraZeneca, Bristol-Myers-Squibb, CIBERSAM, Esteve, FIS-ISCiii, Janssen, Lundbeck, Otsuka, Pfizer and Servier; SR: Consultancy fees from Janssen, Lundbeck and Otsuka; grants from Janssen; GR: Speaker/consultant for Angelini, Innova Pharma, Janssen, Lundbeck and Otsuka; SP: Speaker/consultant for Angelini, Janssen, Lundbeck and Sanofi; JM: Employee of Janssen EMEA; GVD: Employee of Janssen EMEA; YG: Employee of Janssen EMEA; GP: Grant/research support from Angelini; speaker/consultant for Angelini, Janssen, Lundbeck, Neuraxpharm, Sanofi Aventis.
Digibug. Repositorio Institucional de la Universidad de Granada
Publication Estudio, informe, memoria (Report)

Cancer Survivorship and AI for Well-being White Paper: A European research projects collaborative perspective

  • Callejas Carrión, Zoraida|||0000-0001-8891-5237
  • Flynn, Tom
The Cancer Survivorship - AI for Well-being cluster (#CS_AIW) has brought together 11 EU-funded projects working in artificial intelligence (AI) for healthcare and well-being with the aim of transcending the individual project experiences and stop working in silos. The White Paper presents the #CS_AIW initiative and our collective shared vision, providing an overview of the participating projects and it reports on the achievements and lessons learned from our collaboration, including both the benefits obtained and the difficulties addressed. The experience with #CS_AIW to date has proven that collaboration within the cluster has been extremely beneficial and useful to foster an ethos of cross-fertilization engagement, share best practices, boost cross-sector collaboration, increase the participation of end user communities, and reach a wider audience. The activities organized, which encompass meetings, roundtable discussions, podcasts, a better practices guide, a common data space and the white paper itself, have proven to be an inherited valued initiative to generate, activate and communicate knowledge and innovation in the areas of mental health, well-being, cancer recovery, patient support and participatory research., The projects in #CS_AIW have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no.: ASCAPE - Ref 875351 BD4QoL - Ref 875192 CAPABLE - Ref 875052 CLARIFY - Ref 860627 FAITH - Ref 875358 LIFECHAMPS - Ref 875329 MENHIR - Ref 823907 ONCORELIEF - Ref 875392 PERSIST - Ref 875406 QUALITOP - Ref 875171 REBECCA - Ref 65231
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics

  • Heerlein, K.
  • Young, Allan H.
  • Otte, C.
  • Frodl, T.
  • Degraeve, G.
  • Hagedoorn, W.
  • Oliveira Maia, A. J.
  • Pérez Solà, Víctor
  • Rathod, S.
  • Rosso, G.
  • Sierra, Pablo
  • Morrens, J.
  • Van Dooren, G.
  • Gali, Y.
  • Perugi, G.
Background: Treatment resistant depression (TRD; failure to respond to ≥2 treatments) affects ~20% of patients with major depressive disorder (MDD). Real-world data could help describe patient characteristics and TRD disease burden, to assess the unmet needs of TRD patients in Europe. Methods: This observational study collected data from adults with moderate to severe TRD initiating a new treatment for depression, according to local standards of care. At baseline, socio-demographic characteristics, medical history, prior and current treatments were recorded. Disease severity, health-related quality of life (HRQoL), functionality and productivity were assessed. Results: Overall, 411 eligible patients were enrolled across seven European countries. Mean (standard deviation [SD]) patient age was 51.0 (10.8) years; 62.3% were female. Long-term sick leave was reported by 19.0% of patients; 30.2% were unemployed. The mean (SD) duration of the current episode was 2.6 (3.9) years. At baseline, mean (SD) HRQoL scores for EuroQoL 5-dimension 5-level (UK tariff) and EQ-Visual Analog Scale were 0.41 (0.25) and 41.1 (18.7), respectively. The Work Productivity and Activity Impairment questionnaire demonstrated mean (SD) absenteeism of 57.0% (44.9%) and presenteeism of 54.7% (29.5%); mean (SD) overall work impairment was 60.5% (29.9%). Limitations: Key limitations are small cohort size, absence of a control group and generalizability to countries with different healthcare models. Conclusions: TRD patients had a high disease burden, low HRQoL and reduced function and productivity, with a substantial proportion unable to work. This demonstrates an unmet treatment need in TRD patients that, if addressed, could reduce the heavy personal and societal burden., KH: Employee of Janssen EMEA; AHY: Grants from Janssen; speaker/consultant for Allegan, AstraZeneca, Bionomics, Eli Lilly, Janssen, Johnson & Johnson, Livanova, Lundbeck, Servier, Sumitomo Dainippon Pharma and Sunovion; independent research is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health; CO: Speaker/consultant for Allergan, Ferring, Fortbildungskolleg, Limes Kliniken, MedOnline, Medical Tribune, Neuraxpharm, Sage Therapeutics, and Stillachhaus; Research funding from Deutsche Forschungsgemeinschaft, German Federal Ministry of Education and Research and European Union; TF: Speaker for Janssen-Cilag and Recordati; GD: Consultant/speaker for AstraZeneca, BMS, Eli Lilly, EuroGenerics, GSK, Janssen, Lundbeck, Pfizer and Sanofi; WH: Consultant for Janssen; AJOM: Grants from Schuhfried GmBH, Janssen and Compass Pathways, Ltd; investigator-driven research funded by Fundação para Ciência e Tecnologia (PTDC/MED-NEU/31331/2017), Fundação para Ciência e Tecnologia and FEDER (FCT-PTDC/MEC-PSQ/30302/2017-IC&DTLISBOA-01-0145-FEDER) and the European Commission Horizon 2020 program (H2020-SC1-2017-CNECT-2-777167-ΒΟUNCE; H2020-SC1-DTH-2019-875358-FAITH); VPS: Consultancy fees, honoraria or grants from AB-Biotics, AstraZeneca, Bristol-Myers-Squibb, CIBERSAM, Esteve, FIS-ISCiii, Janssen, Lundbeck, Otsuka, Pfizer and Servier; SR: Consultancy fees from Janssen, Lundbeck and Otsuka; grants from Janssen; GR: Speaker/consultant for Angelini, Innova Pharma, Janssen, Lundbeck and Otsuka; SP: Speaker/consultant for Angelini, Janssen, Lundbeck and Sanofi; JM: Employee of Janssen EMEA; GVD: Employee of Janssen EMEA; YG: Employee of Janssen EMEA; GP: Grant/research support from Angelini; speaker/consultant for Angelini, Janssen, Lundbeck, Neuraxpharm, Sanofi Aventis.